Botulinum toxin A - Ipsen

Drug Profile

Botulinum toxin A - Ipsen

Alternative Names: AbobotulinumtoxinA; Azzalure; BoNT-A; BTX-A-HAC NG; Dysport; Dysport NG; Dysport RU; Dysport Solution; Dysport® Next Generation; Reloxin

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Health Protection Agency Porton Down; Ipsen Limited
  • Developer Biosintetica; Galderma; Ipsen Limited; Medicis Pharmaceutical Corporation; Valeant Pharmaceuticals International
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Facial-wrinkles; Fissure in ano; Glabellar lines; Hyperhidrosis; Muscle spasticity; Neurogenic bladder; Spasm; Torticollis
  • Phase III Overactive bladder; Urinary incontinence
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Pain

Most Recent Events

  • 30 Nov 2017 Efficacy data from a phase III extension trial in Muscle spasticity released by Ipsen
  • 29 Nov 2017 Efficacy data from a phase III trial in Muscle spasticity released by Ipsen
  • 27 Jul 2017 Ipsen completes a phase III trial in Muscle Spasticity in Czech Republic, Belgium, Slovakia, before July 2017 (EudraCT2015-000554-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top